Literature DB >> 3757392

Pharmacokinetics of intravenously administered 125I-labelled human alpha 1-acid glycoprotein.

F Brée, G Houin, J Barré, J L Moretti, V Wirquin, J P Tillement.   

Abstract

The volumes of distribution of many acidic drugs have been shown to be close to that of their binding protein, i.e. serum albumin. The distribution of basic drugs mainly bound to alpha 1-acid glycoprotein (AAG) can be questioned with respect to its dependency upon the distribution of this plasma protein. So, a pharmacokinetic study was performed in 7 subjects with human 125I-labelled alpha 1-acid glycoprotein. The steady-state volume of distribution was found to be 5.37 +/- 0.82L. The central volume was 3.23 +/- 0.33L, close to that of plasma volume and the peripheral volume was 2.14 +/- 0.63L. These data allowed the establishment of an equation giving access to the volume of distribution of a basic drug by relating its unbound fraction to physiological distribution of alpha 1-acid glycoprotein. The values yielded by this equation show that the actual and calculated volumes of distribution of basic drugs mainly bound to AAG are discrepant. This protein is thus not the main factor controlling the distribution of basic drugs within the body.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3757392     DOI: 10.2165/00003088-198611040-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  20 in total

1.  Pharmacokinetics of oxprenolol in normal subjects.

Authors:  W D Mason; N Winer
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

2.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

3.  Distribution and metabolism of I131 labeled proteins in man.

Authors:  S A BERSON; R S YALOW
Journal:  Fed Proc       Date:  1957-07

4.  Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation.

Authors:  K M Piafsky; O Borgå
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

5.  Role of concentration-dependent plasma protein binding in disopyramide disposition.

Authors:  P J Meffin; E W Robert; R A Winkle; S Harapat; F A Peters; D C Harrison
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

6.  [Comparative bioavailability of two forms of spironolactone. Rationalization applied to dosage (author's transl)].

Authors:  P d'Athis; M O Richard; D de Lauture; E Rey; M Bouvier d'Yvoire; E Clement; G Olive
Journal:  Therapie       Date:  1981 Jul-Aug       Impact factor: 2.070

7.  Antiepileptic drugs and alpha 1-acid glycoprotein.

Authors:  E Tiula; P J Neuvonen
Journal:  N Engl J Med       Date:  1982-10-28       Impact factor: 91.245

8.  Methadone binding to orosomucoid (alpha 1-acid glycoprotein): determinant of free fraction in plasma.

Authors:  M K Romach; K M Piafsky; J G Abel; V Khouw; E M Sellers
Journal:  Clin Pharmacol Ther       Date:  1981-02       Impact factor: 6.875

9.  Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.

Authors:  J J Lima; H Boudoulas; M Blanford
Journal:  J Pharmacol Exp Ther       Date:  1981-12       Impact factor: 4.030

10.  Intersubject and dose-related variability after intravenous administration of erythromycin.

Authors:  K L Austin; L E Mather; C R Philpot; P J McDonald
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

View more
  10 in total

Review 1.  The role of the protein-binding on the mode of drug action as well the interactions with other drugs.

Authors:  Christine Tesseromatis; Anastasia Alevizou
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

2.  GlycA is a Novel Marker of Inflammation Among Non-Critically Ill Hospitalized Patients with Type 2 Diabetes.

Authors:  Kathleen Dungan; Philip Binkley; Kwame Osei
Journal:  Inflammation       Date:  2015       Impact factor: 4.092

3.  Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure.

Authors:  Ighovwerha Ofotokun; Jeffrey L Lennox; Molly E Eaton; James C Ritchie; Kirk A Easley; Svetlana E Masalovich; Mary C Long; Edward P Acosta
Journal:  J Clin Pharmacol       Date:  2011-01-05       Impact factor: 3.126

Review 4.  Alpha 1-acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function.

Authors:  W van Dijk; E C Havenaar; E C Brinkman-van der Linden
Journal:  Glycoconj J       Date:  1995-06       Impact factor: 2.916

5.  Influence of barrier-crossing limitations on the amount of macromolecular drug taken up by its target.

Authors:  A Aubrée-Lecat; M C Duban; S Demignot; M Domurado; P Fournié; D Domurado
Journal:  J Pharmacokinet Biopharm       Date:  1993-02

6.  Integrated population pharmacokinetic/viral dynamic modelling of lopinavir/ritonavir in HIV-1 treatment-naïve patients.

Authors:  Kun Wang; David Z D'Argenio; Edward P Acosta; Anandi N Sheth; Cecile Delille; Jeffrey L Lennox; Corenna Kerstner-Wood; Ighovwerha Ofotokun
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

7.  Nimesulide binding to components within blood.

Authors:  F Bree; P Nguyen; S Urien; E Albengres; A Macciocchi; J P Tillement
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  Clinical pharmacokinetics of alpha 1-antitrypsin in homozygous PiZ deficient patients.

Authors:  J Constans; P Carles; A Boneu; J Arnaud; A E Tufenkji; M C Pujazon; C Tavera
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

Review 9.  An overview of albumin and alpha-1-acid glycoprotein main characteristics: highlighting the roles of amino acids in binding kinetics and molecular interactions.

Authors:  Michel Bteich
Journal:  Heliyon       Date:  2019-11-21

Review 10.  Pharmacokinetic and Pharmacodynamic Considerations for Drugs Binding to Alpha-1-Acid Glycoprotein.

Authors:  Sherri A Smith; Nigel J Waters
Journal:  Pharm Res       Date:  2018-12-28       Impact factor: 4.200

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.